Lasting HIV injection is one step closer after the second GSK study

Lasting HIV injection is one step closer after the second GSK study https://www.eresviral.com/wp-content/uploads/2018/10/La-inyección-duradera-de-VIH-está-un-paso-más-cerca-después-del-segundo-estudio-GSK

Lasting HIV injection is one step closer after the second GSK study

















The GlaxoSmithKline logo (GSK) is seen at the top of GSK Asia House in Singapore, on March 21, 2018. REUTERS / Loriene Perera





LONDON (Reuters) - A monthly injection to control HIV was as effective as daily pills in a second study conducted by GlaxoSmithKline, paving the way for a new regimen that may be easier for some patients to report to regulators. 

The two-drug experimental injection of cabotegravir and rilpivirine was shown to suppress the HIV virus in a cohort of adults who had not been on a long-term three-day oral regimen, said GSK's HIV unit, ViiV Healthcare. 

In the study, adults with HIV were first put on a daily tablet schedule of three 20-week drugs to suppress the virus before switching to monthly injections. After 48 weeks, the injections maintained a suppression rate similar to that of the pills, he said. 

The results support an important previous study, involving adults who had been using an oral regimen of three medications to control the virus. 

ViiV Healthcare medical director John C. Pottage said the trial provided additional evidence that a long-term injection could offer an alternative to daily oral therapy for people who had previously achieved viral suppression.  

"This innovative dosing regimen could transform HIV therapy by reducing the number of days a person receives treatment from 365 to 12," he said. 

"Working on new methods of HIV treatment, including long-acting injectable therapies, supports our goal of making HIV a smaller part of the lives of people living with HIV." 

ViiV Healthcare, which is also owned by Pfizer and Shionogi, hopes that their work in the development of two-drug therapies will help them compete against Gilead Sciences, the US drugmaker. UU It dominates the HIV market of $ 26 billion a year. 

The company said that the detailed results of the study will be presented at a forthcoming scientific meeting. 





Report by Paul Sandle; Edited by Emelia Sithole-Matarise





Our Rules:The principles of trust of Thomson Reuters.

        .

  !function(f,b,e,v,n,t,s)

  {if(f.fbq)return;n=f.fbq=function(){n.callMethod?

  n.callMethod.apply(n,arguments):n.queue.push(arguments)};

  if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0';

  n.queue=[];t=b.createElement(e);t.async=!0;

  t.src=v;s=b.getElementsByTagName(e)[0];

  s.parentNode.insertBefore(t,s)}(window, document,'script',

  'https://connect.facebook.net/en_US/fbevents.js');

  fbq('init', '369524843414444');

  fbq('track', 'PageView');

    .


SOURCE LINK ERESVIRAL.COM 
https://www.beviral.online